Literature DB >> 1360720

Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.

D P Wang1, I Konishi, M Koshiyama, Y Nanbu, T Iwai, H Nonogaki, T Mori, S Fujii.   

Abstract

The c-erbB-2 (HER-2/neu) protein is a membrane glycoprotein growth factor receptor showing molecular homology with the epidermal growth factor receptor (EGFR). We examined the immunohistochemical reactivity of monoclonal antibodies against both of these proteins in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. The ovarian tumours were classified as benign (16), borderline malignant (2), and malignant (19). Normal surface ovarian epithelium was weakly positive for both c-erbB-2 protein and EGFR. In surface inclusion cysts, however, the epithelial cells lining the lumen exhibited stronger staining for c-erbB-2 protein, but no staining for EGFR. All 16 benign ovarian tumours and the 2 borderline malignant ovarian tumours were positive for c-erbB-2 protein and negative for EGFR. Of the ovarian carcinomas, 13 of the 19 (68.4%) were positive for c-erbB-2 protein and negative for EGFR, while 4 showed positivity for both c-erbB-2 protein and EGFR. Two cases were negative for both proteins. Expression of both c-erbB-2 protein and EGFR was found in endometrioid carcinoma with squamous differentiation and in clinically advanced poorly differentiated serous carcinomas. Expression of c-erbB-2 protein appears to be increased and that of EGFR is reduced in the early stage of epithelial ovarian oncogenesis. The expression of EGFR with c-erbB-2 protein in ovarian carcinoma is related both to histological differentiation and/or advanced clinical stage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360720     DOI: 10.1007/bf01606911

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  19 in total

1.  c-erbB-2 oncogene expression in ovarian cancer.

Authors:  J S Haldane; V Hird; C M Hughes; W J Gullick
Journal:  J Pathol       Date:  1990-11       Impact factor: 7.996

2.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.

Authors:  R Lupu; R Colomer; G Zugmaier; J Sarup; M Shepard; D Slamon; M E Lippman
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

5.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor.

Authors:  G C Rodriguez; A Berchuck; R S Whitaker; D Schlossman; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-03       Impact factor: 8.661

6.  p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases.

Authors:  X L Quian; S J Decker; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

7.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

8.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

Authors:  M F Press; C Cordon-Cardo; D J Slamon
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

9.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

Authors:  A Berchuck; G C Rodriguez; A Kamel; R K Dodge; J T Soper; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-02       Impact factor: 8.661

10.  Epithelial ovarian cancer: a cytokine propelled disease?

Authors:  S Malik; F Balkwill
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more
  8 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Authors:  Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly
Journal:  Clin Cancer Res       Date:  2013-07-30       Impact factor: 12.531

3.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 4.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

5.  Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.

Authors:  M Koshiyama; I Konishi; M Mandai; T Komatsu; S Yamamoto; K Nanbu; T Mori
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Authors:  Achim A Jungbluth; Elisabeth Stockert; H J Su Huang; Vincent P Collins; Keren Coplan; Kristin Iversen; Denise Kolb; Terrance J Johns; Andrew M Scott; William J Gullick; Gerd Ritter; Leonard Cohen; Matthew J Scanlan; Webster K Cavenee; Lloyd J Old; Webster K Cavanee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

7.  Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen.

Authors:  Natalie M Moss; Yueying Liu; Jeff J Johnson; Philip Debiase; Jonathan Jones; Laurie G Hudson; Hidayatullah G Munshi; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2009-06-09       Impact factor: 5.852

Review 8.  Hoxa5: A Key Player in Development and Disease.

Authors:  Lucie Jeannotte; Florian Gotti; Kim Landry-Truchon
Journal:  J Dev Biol       Date:  2016-03-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.